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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
narrowband UVB (NB-UVB) phototherapy in combination with nonsteroidal topical medications
is more effective at repigmentation of vitiligo lesions when compared to NB-UVB therapy alone
in healthy men and women between the ages of 11 and 69.
STUDY DESIGN: Review of three peer-reviewed randomized controlled trials written in
English, two of which were published in 2014, and one in 2011.
DATA SOURCES: Studies were selected based on the method of study, the randomized- control
structure of the studies, and the relevance to the clinical question, and all were identified as
patient-oriented evidence that matters (POEMS).
OUTCOMES MEASURED: A variety of methods were used to evaluate the outcomes of
treatment, including visual analog scale (VAS), Patient Global Assessment (PGA), Investigator
Global Assessment (IGA), VisitrakTM, palm thumb method, vitiligo scoring index (VASI), and
the Lund and Browder (L & B) index.
RESULTS: Three different nonsteroidal topicals were used in conjunction with NB-UVB,
calcipotriol, tetracycline, and 0.1% tacrolimus ointment. Of these three topicals, only 0.1%
tacrolimus ointment in combination with NB-UVB was shown to have a significant result, with a
13.1% reduction in lesions and a P value of 0.005, indicating a difference when compared to
NB-UVB therapy alone. The P values for the other two studies were very similar, with values of
0.557, and 0.566, suggesting they have no enhancing effect when used with NB-UVB.
CONCLUSION: Two of the three studies analyzed concluded that the addition of a nonsteroidal
ointment to NB-UVB was not more effective than NB-UVB alone. The only topical that had
statistical support was 0.1% tacrolimus ointment, an immunosuppressive agent, suggesting that
this topical enhances treatment outcome when used with NB-UVB. NB-UVB is a gold standard
of care for the treatment of generalized vitiligo. Immunosuppressive agents, such as tacrolimus,
when added benefit patients by decreasing a larger area of depigmentation. Further research is
warranted to obtain a better understanding of the role of nonsteroidal immunosuppressive
ointments in vitiligo treatment.
KEY WORDS: vitiligo, NB-UVB, topical tetracycline, tacrolimus
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INTRODUCTION
Vitiligo is an acquired skin disorder that results in macules and patches of
depigmentation most commonly found on sun-exposed areas of skin. Vitiligo is autoimmune in
nature, as the melanocytes, the cells that produce the skin’s pigment, are destroyed. Vitiligo
affects 1% of the world’s population, with generalized vitiligo (vitiligo vulgaris) being the most
common; it is symmetric in distribution and widespread throughout the body. Other types of
vitiligo include acrofacial (extensor surfaces and orifices), segmental, focal, mucosal, and
universal. Vitiligo affects all age groups and races but most often erupts in childhood and early
adulthood. Vitiligo is asymptomatic, but its unsightly appearance draws patients to seek medical
advice and treatment. Interestingly, vitiligo is associated with many other autoimmune disorders,
including hypothyroidism, alopecia areata, and Addison’s disease. Its degree of heritability is
approximately 30%. Some have hypothesized that it is brought on by stress, trauma, or even
sunburn, but none of these causes have been confirmed. Vitiligo is typically a clinical diagnosis,
but a skin biopsy can be completed for a definitive diagnosis. Although vitiligo currently has no
cure, several treatment options are available.
Annually, an average of 1.8 million people visit physician offices with concerns
pertaining to vitiligo, 39,000 seek treatment from hospital outpatient departments, and 137
million dollars are spent on patients with vitiligo. 1 Vitiligo causes psychological anguish in
patients, as they are singled out for looking different. Skin condition is crucial for both mental
and physiological well-being because it influences relationships, occupation, and self-esteem. In
some cultures, patients with vitiligo are completely ostracized. For example, Indian culture
regards vitiligo as Sweta Kustha, meaning, “white leprosy.” 2 Thus, continued research on more
effective treatment options is invaluable to these patients.
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Some popular treatment modalities used include ultraviolet light (sometimes used in
combination with other therapies), corticosteroids, calcineurin inhibitors, excimer lasers/lamps,
and cosmetic interventions. Ultraviolet radiation, particularly NB-UVB, has shown great promise
for those who have extensive generalized vitiligo, and numerous studies have shown that it is
more effective and has less of a side effect profile when compared to ultraviolet A therapy
(PUVA). This type of treatment is time consuming, however, requiring patients to visit their
physician’s office an average of 3 times a week for 6 to12 months. Corticosteroids, on the other
hand, are usually considered first line when lesions are limited (< 10% body surface area [BSA]);
however, this has to be monitored closely because of the risk of skin atrophy. Calcineurin
inhibitors, such as tacrolimus and pimecrolimus, are topicals that do not cause skin atrophy and
are particularly useful when treating vitiligo on the face. Research has begun to look at their
efficacy when used in combination with UVB light and laser treatments, and results are
promising. Evidence regarding other nonsteroidal ointments, such as topical vitamin D analogs
(calcipotriol), is less convincing partly as a result of lack of research. Few studies have looked at
its potential when used in combination with NB-UVB therapy. Another modality, the excimer
lamp/laser, is used for small areas of vitiligo but has not shown superiority to UBV light. Finally,
cosmetic camouflage using dye/pigment preparations can be used for those who do not want
medical intervention. All of these interventions have been proved in at least one setting to
decrease the area of depigmentation in patients with vitiligo. Steroids are typically first line, but
because of the high incidence of skin atrophy, an alternative nonsteroidal is being investigated.
NB-UVB is considered a standard of care, but because it is time consuming, a combined therapy
with nonsteroidal ointment may be able to cut down on light therapy sessions.
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not NB-UVB
phototherapy in combination with nonsteroidal topical medications is more effective at
repigmentation of vitiligo when compared to NB-UVB therapy alone in healthy men and women
between the ages of 11 and 69 years.
METHODS
The criteria for selection included that the population consist of healthy male participants
and healthy female participants who were not pregnant. Participants also had to be older than age
11 years and younger than age 69 years and classified as having stable generalized vitiligo.
Patients also must not have had recent prior treatment. Only randomized controlled right/left
comparative trials that compared NB-UVB therapy in combination with a nonsteroidal
medicated ointment on one side of the patient’s body compared to controlled groups of NB-UVB
therapy alone or in combination with a placebo ointment on the opposite side of that same
patient’s body. The nonsteroidal adjunctive therapy included tacrolimus 0.1% ointment,
calcipotriol ointment, and tetracycline ointment. The outcome was based on the repigmentation
of vitiligo lesions. The studies by Nordal and Kalafi, utilized tacrolimus and tetracycline,
respectively, were randomized, controlled, and double blind. 3,4 The study by Khuller, which
analyzed calcipotriol, was a right/ left prospective comparative trial that did not use a placebo
ointment and was not double blind.5
In order to find ideal articles, the keywords used included vitiligo, NB-UVB, topical
tetracycline, and tacrolimus. These keywords were researched by the author using PubMed in
December 2014. All articles were randomized controlled trials, published in English and peerreviewed, and were selected based on the clinical relevance concerning NB-UVB therapy in
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combination with a nonsteroidal with an appropriate control side of NB-UVB alone or with
placebo ointment. Articles especially needed to address the patients’ concerns with the size of
depigmented lesions in generalized vitiligo. Each study was highly selective regarding inclusion
and exclusion criteria listed in Table 1. Articles were excluded if published before the year 2000,
if participants were younger than 11 or older than 69 years old, if PUVA was used, or if studies
contained a steroidal topical. Statistical values of interest included P values, mean change from
baseline, confidence intervals, absolute benefit increase (ABI), relative benefit increase (RBI),
and number needed to treat (NNT).
Table 1: Demographics and characteristics of included studies

	
  

Study

Type

#
pts

Age
(yrs)

Inclusion Criteria

Exclusion Criteria

W/
D

Interventions

Kalafi,
2014 3

Randomized
controlled
double-blind
placebo study

30

11-66

Generalized, stable
vitiligo
(nonprogressive or
no new lesions in
the previous 3
months)

Pregnant or lactating
patients,
children < 8 years old,
photodermatoses or
cutaneous malignancy,
used other medications
for vitiligo in the
previous 3 months

0

Topical
tetracycline
on one side
vs. Vaseline
placebo on
the other side
twice per day,
NB-UVB
therapy 2-3
times per
week for 12
weeks.

Khullar,
20144

Randomized
right-left
prospective
comparative
clinical trial

27

12-60

Male or female aged
12-60 years,
5-50% of body
surface area,
stable or slowly
progressive disease,
B/L symmetrical
patches;
no topical treatment
in last 2 weeks or
systemic treatment
in previous 4 weeks

Pts with segmental,
universal, palmoplantar, or
mucosal vitiligo,
photosensitivity
dermatoses,
immunosuppression,
impaired liver or renal
function,
hypercalcemia or
hypercalciuria
Urolithiasis,
concomitant use of
medications affecting
calcium metabolism,
pregnant or lactating
women

2

Half of body
topical
calcipotriol
applied
twice/day +
NB-UVB
therapy
(TIW) vs.
UVB therapy
alone on
opposite site
for 24 weeks
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Nordal,
20115

Randomized
controlled trial

46

23-69

> 18 yrs old
Fitzpatrick skin type
II-VI
Symmetric

Pregnant and breast
feeding

6

Tacrolimus
0.1%
ointment on
one side of
body and
Protopic base
placebo
ointment on
opposite side
every
night+NBUVB 3times/
week for 3
mos with 3
mo f/u

OUTCOMES MEASURED
All three studies used slightly different measurements, but all revolved around patientcentered concerns regarding the area of depigmentation. The Kalafi study used the VASI score, a
clinician-used index that measures percent depigmentation, where scores were broken down as
follows: 100% = total depigmentation, 90% = speck of pigmentation, 75% = more depigmented
areas than pigmented areas, 50% = equal pigmented and depigmented areas, 25% = more
pigmented areas than depigmented areas, and 10% = specks of depigmentation.4 The Khuller
study used a combination of L&B index score, a chart that measures BSA affected; IGA, a
subjective reading by the investigator that uses a scale from -1-5 with -1 indicating worsening
and 5 indicating 100% repigmentation; and PGA, a subjective reading from the patient ranging
from 1-10, with 10 indicating maximum disease at baseline. The Nordal study employed the
VAS, a subjective measure by patients on the impact of living with vitiligo. VisitrakTM was used
to obtain an objective measure of vitiligo target lesions. Data from VisitrakTM was converted to
dichotomous data and regarded patients with 20% reduction in depigmentation compared to
placebo as “high responders,” those with less percentage depigmentation considered “low
responders,” and those with the same results on both sides considered “non-responders.”
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RESULTS
Study 1. In a study by Kalafi, 30 patients at an outpatient dermatology office with generalized
and stable vitiligo were selected to participate. Patients were instructed to use tetracycline
ointment twice a day on one side and a Vaseline-based placebo on the opposite side in the same
amount and position. All participants received NB-UVB 2 to 3 times per week, and data for
analysis were collected during the 12th week using VASI. The study gave all values of pre- and
post-VASI scores for both groups. Thus, to convert these points into dichotomous data, a patient
was considered to have benefitted significantly from treatment if there was a 25% decrease in the
area of depigmentation. This method showed that only 1 patient from the treatment side and 1
patient from the placebo side showed significant improvement. There was a significant change
from baseline on both sides, with both sides reporting a P value of 0.026; however, when the
treatment and control side were compared against one another, the P value was recorded as 0.566
(Table 2). The article referred to successful cases as patients who demonstrated any improvement
from baseline, stating that 16.6% of patients who used tetracycline showed improvement.
Likewise, 16.6% of patients who used NB-UVB alone showed a degree of improvement. The
only adverse effect recorded was stinging at the site of application, but data were not provided,
so number needed to harm (NNH) was not calculated. The NNT calculation resulted in an error
message because both treatment modalities had exactly the same effect.
Table 2: Kalafi study: Topical tetracycline + NB-UVB (experiment) vs. NB-UVB alone
(control)
CER (control event
rate)
3%

EER
(experiment
event rate)
3%

Relative Benefit
Increase (RBI)
0

*P value was only considered significant if < 0.05.

	
  

Absolute
Benefit increase
(ABI)
0

Numbers
Needed to Treat
(NNT)
N/A- no
difference
between tx

P value
0.566
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Study 2. Khuller instituted a right/left prospective comparative trial that consisted of 25 patients,
including both male and female participants aged 12 to60 years with 5 to50% of BSA affected,
stable, bilateral symmetrical patches, and no use of topical treatment for previous 2 weeks or
systemic therapy for 4 weeks. The study was randomized as to which side received treatment,
but was not double blind. Calcipotriol ointment was applied twice per day at night and 2 hours
after UVB therapy, which was completed 3 times per week. This study used various modalities,
including L&B index score, IGA, and PGA, to look at change in pigmentation that was of
particular interest. PGA data were collected but not published; therefore, the IGA scores were
transformed into dichotomous data, where patient outcome was considered significant if a 50%
or greater increase in repigmentation occurred (Table 3). Forty-four percent of patients saw 50%
or greater increase in repigmentation on the treatment side; likewise, 44% of patients also
demonstrated 50% or more increase in repigmentation on the placebo side. The L&B index
score, IGA P values, and PGA P values were 0.577, 0.821, and 0.706, respectively, and not
significant. The mean change from baseline for the NB-UVB side alone collected from the three
measurement modalities were 51.4 +/- 28.1 (95% CI 39.8-63), 2.7 +/- 0.5 (95% CI 2.0-3.4), and
5.6 +/- 3.4 (95% CI 4.3-7.0), respectively. The mean changes on the on the calcipotriol side
included 49.0 +/- 24.5 (95% CI 38.9-59.1), 2.5 +/- 0.4 (95% CI 2.0-3.3), and 5.8 +/- 3.2 (95% CI
4.4-7.1). Furthermore, repigmentation did not occur earlier in one group than the other, and
pigment matching to the individual’s skin color was the same in both groups. Repigmentation
onset was between 3 to10 weeks on both sides, and the difference in onset was not statistically
significant, P value = 0.533. Collectively, the data are consistent in that treatment in both groups
was statistically similar. Calcipotriol induced numerous adverse reactions, including erythema,
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xerosios, pruritis, and folliculitis. Nevertheless, an adverse profile of NB-UVB alone was not
presented; thus, NNH was not calculated.
Table 3. Khuller study: Calipotriol + NB-UVB (experiment) vs. NB-UVB alone (control)
CER
(control
event
rate)

EER
(experiment
event rate)

Relative
Benefit
Increase
(RBI)

Absolute
Benefit
Increase
(ABI)

Number
Needed to
Treat
(NNT)

PValue
for
IGA
scores

PValue
for
PGA
scores

P-Value
for L&B

Repigmentati
on onset
measured in
weeks

44%

44%

0

0

N/A- no
difference
in
treatment

0.821

0.706

0.557

0.533

*P value considered significant if < 0.05
Study 3. The study conducted by Nordal researched the usefulness of adding a 0.1% tacrolimus
ointment to NB-UVB therapy using a randomized right/left, double-blind, comparative study.
Forty patients were recruited from a dermatology practice at a university hospital. Pregnant and
breast-feeding patients were excluded likely because tacrolimus is a category C drug. Ointments
were distributed symmetrically every night for 3 months, and NB-UVB therapy was completed 2
to3 times per week with a 3-month follow-up. The data that were presented in the study focused
on target lesion measurements using VisitrackTM; those with 20% improvement compared to
placebo side were considered high responders (9 participants), those with less improvement were
considered low responders (19 participants), and the rest were considered nonresponders.
Overall, there was a median 42.1% decrease in target lesions on the tacrolimus side as compared
to a median of 29% decrease on the placebo side, with a statistical P value of 0.005 (Table 4).
Please note that the data presented within the study could not be converted into a dichotomous
form; thus, ABI, RBI, and NNT could not be calculated. The study also mentions a direct
correlation between an increase in the reduction in target lesion and an increase in the number of
tacrolimus applications; however, this correlation was not seen with an increase in NB-UVB
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treatments. Although subjective scores using VAS were not published, researchers noted that
patients with even minimal improvement responded positively while receiving treatment.
Perioral dermatitis on the tacrolimus side was observed, but no data were published in the study;
therefore, NNH could not be calculated.
Table 4: Nordal study: Percent reduction in target lesions of vitiligo Tacrolimus 0.1%
+NB-UVB 0.1% VS. placebo + NB-UVB
Median % reduction
Median % reduction
Difference
P value
of NB UVB +
of NB-UVB +
Tacrolimus
Placebo
42.1
29.0
13.1
0.005
*P value considered significant if < 0.05
DISCUSSION
The goal of this systematic review was to determine if nonsteroidal ointments in
combination with NB-UVB therapy is more beneficial in the treatment of vitiligo than treatment
with NB-UVB alone. Vitiligo is a highly treatment-resistant condition, and often one modality
does not suffice. NB-UVB has much support in the literature, thus reinforcing its efficacy in
treating generalized vitiligo; however, adjunctive therapies other than topical steroids are less
recognized. Steroid creams have long been a go-to option for clinicians and patients, but they
have a significant side effect profile; therefore, looking into other medicated ointments would be
worthwhile.
Of the 3 nonsteroidal ointments studied, only tacrolimus (0.1%) ointment appears to have
an enhancing effect when used with NB-UVB. Tacrolimus is a calcineurin inhibitor, an
immunosuppressant, and blocks the release of inflammatory cytokines. Tacrolimus is commonly
prescribed to treat atopic dermatitis, although it recently has gained attention for its potential to
treat psoriasis, pyoderma gangrenosum, lichen planus, and vitiligo. A black-box warning on the
product reports weak linkage between tacrolimus use and malignancy (skin and lymphoma);
thus, the manufacturers recommend short-term and minimal use. This contradicts the previous
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misconception that a nonsteroidal would be a better option for long-term topical application,
especially when tacrolimus quantity and length of use seem to have a direct benefit on vitiligo.
Nonetheless, more research needs to be completed to obtain a better understanding of the
association. Topical tetracycline (indicated for impetigo and perioral dermatitis) and calcipotriol
(indicated for plaque psoriasis) have safer profiles, but after analyzing both studies, they appear
to have no benefit when used as an adjunctive therapy.
Larger studies need to be performed; the studies included in this review were limited with
40, 30, and 25 participants. Also, the quality of the Khullar study was undesirable because it was
not double blind and did not utilize a placebo ointment. The study was also male dominant with a
4:1 ratio, did not include an age range of participants, and included 3 acrofacial types of vitiligo,
while this review focused on the generalized vitiligo type. The study also focused on darker skin
types III-V. The Kalafi study exclusively looked at Fitzpatrick skin type III and included
adolescents and children in the study aged 11-17 years. The Nordal study looked exclusively at
adults, predominantly women, and the majority of patients studied were Fitzpatrick skin type III
(22 participants), IV (11 participants), V (1 participant), and VI (1 participant). The sites of
application varied widely among the three studies, including the knees, arms, face, neck, and
trunk; each study looked at a combination of these sites. This may be significant because sources
have identified that tacrolimus may be most beneficial for the head and neck.6 Ideally, studies
would consist of equal gender, consist of adults or children exclusively, consist of an array of
skin types with race included, and focus on a certain anatomical site. As a result of the many
discrepancies across these topics, these results cannot be generalized to everyone, only to those
mentioned in the respective studies.
CONCLUSION
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After review of the 3 studies, the benefit of nonsteroidals as an adjunctive therapy is
inconclusive. All three nonsteroidal were chosen because they have a mechanism that has
potential to induce repigmentation. Calcipotriol activates a pathway to stimulate melanocyte
production; whereas tetracycline and tacrolimus reduce inflammatory cytokines. Tacrolimus was
the only successful therapy in enhancing the effects of NB-UVB. This systemic review was
intended to be broad to work as a starting point for future research. Since tacrolimus had the
most promise, a look at different calcineurin inhibitors would be interesting to see if one has
more of an enhancing effect with NB-UVB than the others, thus potentially lessening
phototherapy sessions and long-term corticosteroid use. Before additional research in this area
can begin, however, more research concerning the association between tacrolimus and
malignancy, specifically analyzing quantities and time frames in which risk is likely to occur
must be completed. Future studies can improve the knowledge base on this topic by focusing on
a wide range of skin pigment types, specifying a pediatric or adult study, and focusing on
specific anatomical sites.

	
  

REFERENCES
1. Chronic Condition of skin appearance. In: The Burden of Skin Diseases. Falls Church,
VA: The Lewin Group, Inc.; 2005:66-68.
2. Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health and
Quality of Life Outcomes. 2003;1:58. doi:10.1186/1477-7525-1-58
3. Nordal EJ, Guleng GE, Ronnevig JR. Treatment of vitiligo with narrowband-UVB
(TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized
right/left double blind comparative study. J Eur Acad Dermatol Venereol.
2011;25(12):1440-1443.
4. Kalafi A, Jowkar F. Evaluation of the efficacy of topical tetracycline in enhancing the
effect of narrow band UVB against vitiligo: a double blind, randomized, placebocontrolled clinical trial. ISRN Dermatol. 2014;2014:472546.
5. Khullar G, Kanwar AJ, Singh S, Parsad D. Comparison of efficacy and safety profile of
topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the
treatment of vitiligo: a 24-week prospective right-left comparative clinical trial. J Eur
Acad Dermatol Venereol. 2014.
6. Vitiligo treatment & management: medical care, surgical care, consultations.
http://emedicine.medscape.com/article/1068962-treatment. Published 2015. Accessed
November 22, 2015.

	
  

